The Hawaii Parkinson’s & Movement Center and Hawaii Parkinson’s Research Unit have been awarded Hawaiʻi’s first clinical research study focused on Lewy Body Dementia (LBD). This landmark study investigates ACP-204 (remlifanserin), an investigational medication developed to treat hallucinations and delusions…
Researchers at the Hawaii Parkinson’s Disease Center and Hawaii Parkinson’s Research Unit are participating in groundbreaking research evaluating prasinezumab, an investigational monoclonal antibody that may become the first disease-modifying treatment to slow the progression of Parkinson’s disease. This research is…
